<![CDATA[Novo Nordisk A/S - Stock Exchange Announcements]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]><![CDATA[Novo Nordisk A/S purchases B shares worth DKK 1.0 billion from Novo A/S as part of the ongoing share repurchase programme]]>
]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]><![CDATA[Financial statement for the period 1 January 2008 to 30 June 2008]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]><![CDATA[Novo Nordisk files for regulatory approval of liraglutide in Japan]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]><![CDATA[Status re Novo Nordisk's holding of its own shares (30 June 2008)]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]><![CDATA[Total number of voting rights and share capital in Novo Nordisk A/S as of 30 June 2008.]]><![CDATA[Novo Nordisk receives approval in the US for PrandiMet(TM)]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]><![CDATA[Significant weight loss sustained in obese people treated with liraglutide for one year]]><![CDATA[Reduction of the share capital and status of holding of own shares (13 June 2008)]]><![CDATA[Novo Nordisk discontinues phase 3 clinical trial with NovoSeven® in trauma]]>